Adalat and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Adalat (nifedipine), especially for people who are female, 60+ old, also take Lipitor, and have Gastrointestinal stromal tumor.

The phase IV clinical study analyzes which people have Hearing loss when taking Adalat. It is created by eHealthMe based on reports of 20,643 people who have side effects when taking Adalat from the FDA, and is updated regularly.

What is Adalat?

Adalat has active ingredients of nifedipine. It is often used in high blood pressure. eHealthMe is studying from 20,940 Adalat users. Check the latest studies of Adalat.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,386 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 18, 2026

20,643 people reported to have side effects when taking Adalat.
Among them, 23 people (0.11%) have Hearing loss.

Among these 23 people:

What is the gender of people who have Hearing loss when taking Adalat? *

female: 52.17 %
male: 47.83 %

What is the age of people who have Hearing loss when taking Adalat? *

What are other drugs people take besides Adalat? *

What are other side effects people have besides Hearing loss? *

Pleural Effusion (water on the lungs): 6 people, 26.09%
Renal Impairment (severely reduced kidney function): 5 people, 21.74%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 17.39%
Abdominal Distension: 4 people, 17.39%
Liver Disorder (liver diseases): 4 people, 17.39%
Face Oedema (swelling of face): 4 people, 17.39%
Multi-Organ Failure (multisystem organ failure): 3 people, 13.04%
Haemoglobin Decreased: 3 people, 13.04%
Dehydration (dryness resulting from the removal of water): 3 people, 13.04%
Muscle Aches (muscle pain): 3 people, 13.04%

What are the existing conditions these people have? *

Gastrointestinal Stromal Tumor: 3 people, 13.04%
Postpartum Depression (depression suffered by a mother following childbirth): 2 people, 8.70%
Pain: 2 people, 8.70%
Colon Cancer: 2 people, 8.70%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 4.35%
Sinusitis Bacterial (bacterial infection of sinus): 1 person, 4.35%
Pulmonary Congestion (congestion in the lungs): 1 person, 4.35%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 4.35%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.35%
High Blood Cholesterol: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Adalat and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adalat:

Adalat (20,940 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Adalat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,386 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on nifedipine (the active ingredients of Adalat) and Adalat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.